- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Jazz Pharmaceuticals (Nasdaq: JAZZ) hit a new 52-week high Tuesday as it is currently trading at $59, above its previous 52-week high of $58.94 with 54,747 shares traded as of 9:40 a.m. ET. Average volume has been 782,600 shares over the past 30 days. Jazz has a market cap of $3.28 billion and is part of the health care sector and drugs industry. Shares are up 50.8% year to date as of the close of trading on Monday. Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, focuses on the identification, development, and commercialization of pharmaceutical products to meet unmet medical needs. The company has a P/E ratio of 23.7, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.